A Sequential, Two-Part Study to Evaluate the Clinical Benefit, Safety, Pharmacokinetics, and Pharmacodynamic of AT-007 in Pediatric Subjects With Classic Galactosemia (CG)
Latest Information Update: 02 Aug 2024
At a glance
- Drugs Govorestat (Primary)
- Indications Galactosaemia
- Focus Biomarker; Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Applied Therapeutics
- 02 Aug 2024 Planned primary completion date changed from 1 Apr 2023 to 1 Dec 2024.
- 31 Jul 2024 Planned End Date changed from 1 Sep 2023 to 1 Dec 2024.
- 23 Mar 2023 According to an Applied Therapeutics media release, company is looking forward to the data readouts in the year ahead.